Therefore, the fact that GLI1 inhibitors like GANT61 may inhibit tumour cell growth, whereas SMO inhibitors have no effect, cannot be used as evidence for a non-canonical HH pathway [68,84]. Here, GLI1 is linked to neoplasm.